Immune cell biochemical abnormalities in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 15, Issue 6, 1997, Pages 677-684

  Liossis, S N C ^a   Vassilopoulos, D ^b   Kovacs, B ^b   Tsokos, G C ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

B cells; Signal transduction; SLE; T cells

Indexed keywords

APOPTOSIS; B LYMPHOCYTE; CALCIUM MOBILIZATION; CHROMOSOME ABERRATION; DATA ANALYSIS; DISEASE ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0030859688     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. TSOKOS GC: Overview of cellular immune function in systemic lupus erythematosus. In: LAHITA RG (Ed.): Systemic Lupus Erythematosus, New York, Churchill Livingstone Inc. 1992; 15-50.
2. TSOKOS GC: Biochemical and molecular abnormalities in the pathogenesis of systemic lupus erythematosus. Clin Exp Rheumatol 1991; 9: 533-9.
3. KAMMER GM, KHAN I, MALEMUD C: Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 1994; 94: 422-30.
4. LAXMINARAYANA D, KAMMER GM: Diminished expression of type I protein kinase A RIα and RIβ transcripts in SLE T lymphocytes. Arthritis Rheum 1996; 39: S249.
5. WEISS A, LITTMAN DR: Signal transduction by lymphocyte antigen receptor. Cell 1994; 76: 263-74.
6. CAMBIER JC, PLEIMAN CM, CLARK MR: Signal transduction by the B cell receptor and its coreceptors. Annu Rev Immunol 1994; 12: 457-86.
7. WANGE RL, SAMELSON LE: Complex complexes: signaling at the TCR. Immunity 1996; 5: 197-205.
8. COGGESHALL KM, MCHUGH JC, ALTMAN A: Predominant expression and activation-induced tyrosine phosphorylation of phospholipase C-γ2 in B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 5660-4.
9. VASSILOPOULOS D, KOVACS B, TSOKOS GC: TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995; 137: 2269-81.
10. LIOSSIS SNC, KOVACS B, DENNIS G, KAMMER GM, TSOKOS GC: B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98: 2549-57.
11. SLOAN-LANCASTER J, STEINBERG TH, ALLEN PM: Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 1996; 184: 1525.
12. HARDING FA, MCARTHUR JG, GROSS JA, RAULET DH: CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (London) 1992; 356: 607-9.
13. BOUSSIOTIS VA, BARBER DL, LEE BJ, GRIBBEN JG, FREEMAN GJ, NADLER LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 1996; 184: 365-76.
14. KRUMMEL MF, ALLISON JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-65.
15. SFIKAKIS PP, OGLESBY R, SFIKAKIS P, TSOKOS GC: B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Clin Exp Immunol 1994; 96: 8-14.
16. TSOKOS GC, KOVACS B, SFIKAKIS PP, THEOCHARIS S, VOGELGESANG SA, VIA CS: Defective antigen-presenting cell function in patients with systemic lupus erythematosus: Role of the B7-1 (CD80) costimulatory molecule. Arthritis Rheum 1996; 39: 600-9.
17. HOLLENBAUGH D, OCHS HD, NOELLE RJ, LEDBETTER JA, ARUFFO A: The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 1994; 138: 23-37.
18. KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-37.
19. DESAI-MEHTA A, LU L, RAMSEY-GOLDMAN R, DATTA SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-73.
20. WILSON HA, GREENBLATT D, TAYLOR CW, PUTNEY JW, TSIEN RY, FINKELMAN FD, CHUSED TM: The B lymphocyte calcium response to anti-Ig is diminished by membrane immunoglobulin crosslinkage to the Fcγ receptor. J Immunol 1987; 138: 1712-8.
21. FRANK MM, HAMBURGER MI, LAWLEY TJ, et al.: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1993; 300: 518-23.
22. SALMON JE, MILLARD SS, SCHACHTER LA, et al.: FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-54.
23. KORETZKY GA: Role of the CD45 tyrosine phosphatase in signal transduction in the immune system. FASEB J 1993; 7: 420-6.
24. CZYZYK J, FERNSTEN P, SHAW M, WINFIELD JB: Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 592-9.
25. LINKER-ISRAELI M, WALLACE DJ, PREHN JL, NAND R, LI L, KLINENBERG JR: A greater variability in the 3′-flanking region of the IL-6 gene in patients with systemic lupus erythematosus. Autoimmunity 1996; 23: 199-209.
26. DAVIS VA, MILLINGTON M, HYLAND V, LAWFORD R, HUANG Q, GRENNAN D: Increased frequency of the uncommon allele of a tumor necrosis alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995; 12: 127-33.
27. LLORENTE L, ZOU W, LEVY Y, et al.: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-44.
28. JACOB CO, FRONEK Z, LEWIS GD, KOO M, HANSEN JA, MCDEVITT HO: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci 1990; 87: 1233-7.
29. WILSON AG, GORDON C, DI GIOVINE FS, et al.: A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994; 24: 191-5.
30. BARCELLINI W, RIZZARDI GP, BORGHI MO, et al.: In vivo type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996; 5: 139-45.
31. DOEFLER W: DNA methylation and gene activity. Annu Rev Biochem 1983; 52: 93-124.
32. YUNG RL, RICHARDSON BC: Role of T cell DNA methylation in lupus syndromes. Lupus 1994; 3: 487-91.
33. RICHARDSON B, SCHEINBART L, STRAHLER J, GROSS L, HANASH S, JOHNSON M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33: 1665-73.
34. RICHARDSON BC, STRAHLER JR, PIVIROTTO TS, et al.: Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 1992; 35:647-62.
35. LIEBERMAN MW, BEACH RL, PALMITTER RD: Ultraviolet radiation-induced metallothionein-I gene activation is associated with extensive DNA demethylation. Cell 1983; 35: 207-14.
36. BOISE LH, THOMPSON CB: Hierarchical control of lymphocyte survival. Science 1996; 247: 67-8.
37. MYSLER E, BINI P, DRAPPA J, et al.: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029-34.
38. ARINGER M, WINTERSBERGER W, STEINER CW, et al.: High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1423-30.
39. KOVACS B, LIOSSIS SNC, DENNIS GJ, TSOKOS GC: Increased expression of functional Fas ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997 (in press).
40. KOVACS B, VASSILOPOULOS D, VOGELGESANG SA, TSOKOS GC: Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-α. Clin Immunol Immunopathol 1996; 81: 293-302.
41. LORENZ HA, GRÜNKE M, HIERONYMUS T, et al.: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997; 40: 306-17.
42. CHENG J, ZHOU T, LIU C, et al.: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
43. MOUNTZ JD, WU J, CHENG J, ZHOU T: Autoimmune disease: A problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-20.
44. ELKON KB: Apoptosis in SLE-too little or too much? Clin Exp Rheumatol 1994; 12: 553-9.
45. DRAPPA J, VAISHNAW AK, SULLIVAN KE, CHU JL, ELKON KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335: 1643-9.
46. LE DEIST F, EMILE JF, RIEUX-LAUCAT F, BENKERROU M, ROBERTS I, BROUSSE N, FISHER A: Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996; 348: 719-23.
47. WU J, WILSON J, HE J, XIANG L, SCHUR PH, MOUNTZ JD: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107-13.
48. KOVACS B, SZENTENDREI T, BEDNAREK JM, et al.: Persistent expression of a soluble form of Fas/APO-1 in continuously activated T-cells from a patient with SLE. Clin Exp Rheumatol 1997; 15: 19-23.